Innate Pharma, Inc.

Innate Pharma reported H1 2024 financials and clinical updates, including $12.3M revenue, $38.7M operating expenses, and $102.1M cash reserves. Lacutamab, an orphan drug, showed promising results in trials and received FDA designation. The ANKET platform advanced with SAR443579 in Phase 2 and IPH6501 in clinical trials. IPH45, an ADC targeting Nectin-4, is moving to Phase 1. The company aims to address unmet oncology needs and expects clinical data in the coming years.

Innate Pharma reports H1 2024 results: positive lacutamab Phase 2 in mycosis fungoides at ASCO 2024, NK-Cell engager SAR443579/IPH6101 advances to Phase 2, IPH45 (Nectin-4 ADC) progressing towards Phase 1, monalizumab data in early NSCLC presented at WCLC, cash position of €102.1 million, and a conference call at 2:00 p.m. CEST.